Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ardent Health (ARDT) Cash & Equivalents (2023 - 2025)

Ardent Health (ARDT) has 3 years of Cash & Equivalents data on record, last reported at $609.4 million in Q3 2025.

  • For Q3 2025, Cash & Equivalents rose 8.22% year-over-year to $609.4 million; the TTM value through Sep 2025 reached $609.4 million, up 8.22%, while the annual FY2024 figure was $556.8 million, 27.24% up from the prior year.
  • Cash & Equivalents reached $609.4 million in Q3 2025 per ARDT's latest filing, up from $540.6 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $609.4 million in Q3 2025 and bottomed at $334.5 million in Q2 2024.
  • Average Cash & Equivalents over 3 years is $505.3 million, with a median of $540.6 million recorded in 2025.
  • The widest YoY moves for Cash & Equivalents: up 61.6% in 2025, down 8.22% in 2025.
  • A 3-year view of Cash & Equivalents shows it stood at $437.6 million in 2023, then grew by 27.24% to $556.8 million in 2024, then grew by 9.46% to $609.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash & Equivalents were $609.4 million in Q3 2025, $540.6 million in Q2 2025, and $495.0 million in Q1 2025.